Banned medicine (Credit-Canva)
The Union Health Ministry implemented a ban on 156 "irrational" FDC medicines, effective immediately. These medicines, including widely used antibiotics, painkillers, and multivitamins, were commonly used to treat fever, cough, and infections. The ban was imposed due to the associated health risks and lack of therapeutic justification for the ingredients in these FDCs.
FDCs or fixed-dosed combinations, also known as "cocktail drugs," are medications that combine multiple drugs in a single pill. They are designed to treat multiple symptoms or conditions simultaneously. While they offer convenience, they can pose significant risks. These risks include the possibility of overdose, adverse interactions between the drugs, and the development of antibiotic resistance. Additionally, many FDC medicines lack sufficient scientific evidence to support their safety and efficacy.
Experts have raised concerns about the use of FDC medicines. They believe that many of these combinations lack sufficient scientific evidence to support their safety and effectiveness. Additionally, the combination of multiple drugs in a single pill can increase the risk of adverse side effects and interactions with other medications.
Experts have also found that FDC medicines may not be as effective as individual drugs in treating certain conditions. It is important to note that safer and more effective alternatives are available for most of the medical conditions that FDC medicines were used to treat. One particular concern is the inclusion of antibiotics in some FDCs. Overuse of antibiotics can contribute to the development of antibiotic resistance, a major public health threat.
The use of FDC medicines can lead to adverse effects, including serious ones. Additionally, safer alternatives, tested in clinical trials, are available to treat the same medical conditions. Experts recommend prescribing drugs individually based on a patient's clinical symptoms rather than combining them in FDCs.
The ban on irrational FDC medicines by the Union Health Ministry can be seen as a positive step towards promoting rational drug use and protecting public health. The goal is to eliminate unnecessary and potentially harmful drug combinations. This is a step forward in reducing the risks associated with medication and ensure safer and more effective treatment options for patients.
Credits: Canva
A sudden and unusually early rise in norovirus infections, often called the “winter vomiting disease”, has been reported across the United States, adding yet another health concern to a season already crowded with respiratory illnesses, as noted by Axios. Figures from the Centers for Disease Control and Prevention (CDC) show that positive norovirus tests have doubled over recent weeks, climbing from seven percent in August to 14 percent by mid-November.
This spike has arrived sooner than expected and at a time when cases of COVID, whooping cough, and seasonal flu are also climbing.
Norovirus leads to intense vomiting and diarrhea because it irritates the stomach and intestines, as described by the CDC. This has earned it the informal name “extreme vomiting disease.”
It is the most frequent cause of vomiting and diarrhea in the country. Nearly 20 million people deal with norovirus each year, according to Scientific American. It is different from the common “stomach bug” or “stomach flu” and has no link to the influenza virus.
Symptoms typically appear 12 to 48 hours after exposure and often include:
Less often, people may also experience fever, headaches, or body aches.
Norovirus outbreaks can affect anyone, but children and older adults face a higher chance of serious illness, the CDC notes. Since several strains of the virus exist, people may get sick more than once. Genetics may also influence how likely someone is to catch it.
Also Read: Your Morning Orange Juice Might Be Shaping Thousands Of Immune Genes At Once
Health officials describe norovirus as extremely contagious. It spreads quickly through droplets, contaminated surfaces, or unsafe food.
Norovirus is a human virus usually spread through the fecal-oral route,” explained Robyn Chatman, a Cincinnati physician, to the American Medical Association. This means the virus can transfer from contaminated hands to the mouth during routine activities. It can remain on surfaces for days or even weeks and moves rapidly in crowded places such as nursing homes, child care centers, and cruise ships, the AMA notes.
A norovirus “outbreak,” as defined by the CDC, occurs when two or more similar illnesses stem from the same suspected or confirmed source. The CDC records about 2,500 such outbreaks each year.
Between August 1 and November 13, 153 outbreaks were reported. By comparison, only 69 outbreaks had been recorded by the final week of November last year. In early December 2023, the U.S. logged 65 outbreaks, according to AP.
Everyday Health reports that a new norovirus strain may be contributing to the current jump in cases. For many years, most infections were linked to the strain GII.4. Now another strain, GII.17, has become dominant, responsible for around 75 percent of outbreaks during the 2024–2025 season, up from about 10 percent during 2022–2023.
There is no specific treatment for norovirus, as Cleveland Clinic explains. The infection needs to run its course. Staying well-hydrated, resting, and choosing mild, easy-to-digest foods can help ease symptoms. Seek medical care if you cannot keep fluids down or if your symptoms continue beyond three days.
To prevent spreading the virus, the CDC advises avoiding food preparation or caring for others until at least 48 hours after symptoms stop.
Credits: iStock
The World Health Organization (WHO) issued its first-ever recommendation endorsing GLP-1 medications as part of a long term strategy to manage obesity in adults. Earlier, in the guidance to deal with obesity, the main focus was given to diet and lifestyle changes. Thus, this is a big shift from how the UN agency has traditionally approached obesity treatment.
Until now, WHO guidelines only focused on lifestyle changes including physical activity and diet. The new recommendation acknowledges that medication can play a supportive role when combined with counseling on healthy eating and regular exercise.
Published in the Journal of the American Medical Association (JAMA), the guideline describes long-term use as continuous treatment for at least six months. In its note, WHO called obesity a “chronic, relapsing disease” that affects more than one billion people worldwide and contributes substantially to illness, early death, and economic strain on health systems. GLP-1 therapies, the organization wrote, offer “clinically meaningful weight loss and broad metabolic benefits” when used appropriately.
GLP-1 drugs mimic the action of the natural hormone GLP-1 to regulate blood sugar and promote weight loss. They work by increasing insulin release in a glucose-dependent manner, decreasing the liver's production of glucagon, and slowing down the emptying of the stomach, which helps lower blood sugar levels after a meal. They also act on the brain to suppress appetite and increase feelings of fullness, leading to reduced calorie intake.
In people with type 2 diabetes, notes Harvard Health, the body's cells are resistant to the effects of insulin and body does not produce enough insulin, or both. This is when GLP-1 agonists stimulate pancreas to release insulin and suppress the release of another hormone called glucagon.
These drugs also act in the brain to reduce hunger and act on the stomach to delay emptying, so you feel full for a longer time. These effects can lead to weight loss, which can be an important part of managing diabetes.
In September, WHO added GLP-1 drugs to its list of essential medicines, but only for treating diabetes, not for obesity alone. The new guideline extends that conversation, offering a more formal stance on their use in obesity management. The recommendations were developed by a committee of experts in obesity, pharmacology, and public health, following requests from several WHO member states. They also align with approvals already granted by regulators like the U.S. Food and Drug Administration.
Obesity is now recognized as one of the most widespread health concerns worldwide, linked to an increased risk of chronic conditions, including cancers, heart disease, and metabolic disorders. Beyond physical health, it also impacts mental well-being and quality of life. With more than a billion people affected globally, the economic burden on healthcare systems continues to grow.
Also Read: Only 1 in 10 People With Obesity Have Access To Popular GLP-1 Weight-Loss Drugs, Says WHO
However, the accessibility still remains a major issue. n the United States, the most widely used medications: Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, carry list prices exceeding $1,000 per month. Recently, the Trump administration announced agreements with pharmaceutical companies aimed at lowering costs for people paying out of pocket or covered under Medicare or Medicaid.
Credits: iStock
Every year on December 3, the International Day of Persons with Disabilities (IDPD) is observed. It is a UN day that works towards promoting the rights and well-being of persons with disabilities at every level of society and development, and to raise awareness of the situation of personal with disabilities in all aspects of life.
At the headquarters of the World Health Organization (WHO), IDPD events are organized to educate the public, raise awareness, advocate for political will and resources, and celebrate WHO's achievement.
As per the United Nations Convention on the Rights of Persons with Disabilities or the UNCRPD, persons with disabilities are individuals with long-term physical, mental, intellectual, or sensory impairments that restrict their ability to participate in society on equal terms.
India’s commitment to accessibility stems from Article 9 of the UNCRPD, which mandates equal access to physical spaces, transportation, and services.
Rights of Persons with Disabilities Act, 2016: India’s RPwD Act, 2016, aligns with this definition and adds the term “benchmark disability,” which refers to individuals with at least 40% of a specified disability.
This Act sets accessibility standards for public spaces and digital platforms.
The Act increased reservation for PwDs from 3% to 4% in jobs and 3% to 5% in higher education.
The RPwD Act expanded the list of disabilities from 7 to 21 categories, including conditions like:
As per the 2011 Census, India is home to 26.8 million persons with disabilities, which means at least 2.21% of its total population. The highest prevalence is observed between the age group of 10 to 19 years. Among them, 20% have mobility impairments, 19% have visual impairment, 19% have hearing impairment, and 8% suffer from multiple disabilities.
This year, the theme is 'Fostering disability-inclusive societies for advancing social progress, while in 2024, the theme was: 'Amplifying the leadership of persons with disabilities for an inclusive and sustainable future'.
This was first established by the United Nations in 1992, to raise awareness and creating inclusive society for all. The aim was to create an inclusive, accessible, and equitable society where no one is left behind.
The main role of this day in observance is to educate people. As more than 1 billion people in the world, which is around 20% of the world population live with some kind of disability. Thus, in such a scenario it is important for people to be sensitive towards their need. This day also helps address and solve the barriers faced by people living with disabilities, which include:
Limited access to education and employment
Inaccessible public spaces and transportation
Social stigma and discrimination
Insufficient healthcare and rehabilitation services
Lack of assistive technologies and accessible digital platforms
© 2024 Bennett, Coleman & Company Limited